'No Second China': EU Firms Face Coronavirus Fallout

The general economic and business impact on European firms from the coronavirus in China is widespread and severe, and companies must consider diversifying, warns an influential European trade group in a just-released business survey. But it concedes there are no China alternatives.

Coronavirus
EU Firms In China Feel Coronavirus Impact • Source: Shutterstock

The demand for products and services has been slashed, manufacturing disrupted and the supply chain is running out. The impact from the ongoing coronavirus outbreak in China is only starting to surface, with possible diversification of sourcing one key topic that has been thrown up for the global pharma industry.

10 days since most offices reopened and workers started slowly returning to work, many companies are still operating on uneven...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.